O-1602

• Description :

  O-1602 is an agonist of GPR55 (G protein-coupled receptor 55) . O-1602 reduces the number and activation of hippocampal microglia induced by METH (methamphetamine) . O-1602 decreases the expression levels of NLRP3 inflammasome proteins, including NLRP3, ASC and Caspase-1[1].

• UNSPSC :

  12352005

• Hazard Statement :

  H225, H319, H336

• Target :

  GPR55

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein; Neuronal Signaling

• Field of Research :

  Neurological Disease

• Assay Protocol :

  https://www.medchemexpress.com/o-1602.html

• Concentration :

  10mM

• Purity :

  99.68

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  CC1=C([C@H]2[C@@H](CCC(C)=C2)C(C)=C)C(O)=CC(O)=C1

• Molecular Formula :

  C17H22O2

• Molecular Weight :

  258.36

• Precautions :

  H225, H319, H336

• References & Citations :

  [1]Jinlong Zhang, et al. GPR55 activation improves anxiety- and depression-like behaviors of mice during methamphetamine withdrawal.Heliyon, 10 (2024), e30462.|[2]A. Díaz-Arteaga, et al. The atypical cannabinoid O-1602 stimulates food intake and adiposity in rats. Diabetes, Obesity and Metabolism. March 2012, Volume14, Issue3.|[3]Peng Ma, et al. IAVPGEVA: Orally Available DPP4-Targeting Soy Glycinin Derived Octapeptide with Therapeutic Potential in Nonalcoholic Steatohepatitis.Journal of Agricultural and Food Chemistry. 2024, 72, 13, 7167–7178.

• Shipping Conditions :

  Dry Ice

• Storage Conditions :

  -80°C

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [317321-41-8]